Evidence map›Paper›PMID 19752747›Full record

ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2009

Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.

Franz O Smith, Jacob A Klapper, John R Wunderlich, Steven A Rosenberg, Mark E Dudley

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  5. Article
  6. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Franz O SmithSurgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892-1201, USA.
Jacob A Klapper
John R Wunderlich
Steven A Rosenberg
Mark E Dudley
National Cancer Institute · US

Funding

Adoptive Cell Transfer Immunotherapy of CancerZIABC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2025
$56.8M
Surgery Branch Cell Prep CoreZICBC010905 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HALAS, HYUNMI · 2009 to 2025
$23.9M
Cell Production Facility CoreZICBC011020 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DUDLEY, MARK · 2009 to 2013
$6.5M
Adoptive Cell Transfer Immunotherapy of CancerZ01BC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2008 to 2008
$1.5M
Intramural NIH HHS Z01 BC010984
6 · The paper itself

Abstract

A patient with metastatic melanoma who had progressive disease after prior surgical resections, high dose interleukin-2, and anti-cytotoxic T lymphocyte antigen-4 antibody received sequential treatments with autologous tumor infiltrating lymphocytes that recognized the gp100 melanocyte differentiation antigen. Although no clinical response was seen when cells were administered alone, an objective clinical response to therapy was seen with tumor infiltrating lymphocytes administered together with a highly immunogenic fowlpox vaccine expressing a gp100: 209-217 (210M) epitope. Persistence of the transferred antigen-specific lymphocytes in the peripheral blood was observed only after adoptive cell therapy plus administration of vaccine. Cell proliferation in vitro was further stimulated by additional vaccine and interleukin-2. The patient has an ongoing partial response at 10 months after the last treatment.

Indexed as

Fowlpox virusImmunotherapy, AdoptiveBlood Transfusion, AutologousCell ProliferationDisease ProgressionEpitopes, T-LymphocyteFacial Neoplasmsgp100 Melanoma AntigenHumansLymphocytes, Tumor-InfiltratingMaleMelanomaMembrane GlycoproteinsMiddle AgedNeoplasm MetastasisViral VaccinesEpitopes, T-Lymphocytegp100 Melanoma AntigenMembrane GlycoproteinsPMEL protein, humanViral Vaccines

Identifiers

PMID19752747
PMCPMC6290459
OpenAlexW2093042990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.